Bivalirudin Research Dosage: Published Protocol Reference
Bivalirudin dosage references vary by route and study context. The database lists Intravenous bolus + infusion: 0.75 mg/kg bolus, then 1.75 mg/kg/h, During PCI, continued for up to 4 hours post-procedure and Intravenous infusion: 0.15-0.2 mg/kg/h, Continuous (for HIT patients). These are research-context references, not a universal protocol.
Direct Answer
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research
Research Dosage References
- <strong>Intravenous bolus + infusion</strong> - 0.75 mg/kg bolus, then 1.75 mg/kg/h - During PCI, continued for up to 4 hours post-procedure - ACT should be checked 5 minutes after bolus. Additional bolus of 0.3 mg/kg if ACT <225 seconds. Reduce infusion to 1 mg/kg/h with GFR <30 mL/min.
- <strong>Intravenous infusion</strong> - 0.15-0.2 mg/kg/h - Continuous (for HIT patients) - Used as anticoagulant in patients with heparin-induced thrombocytopenia. Titrate to aPTT 1.5-2.5x control.
Half-Life
~25 minutes (normal renal function).
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Bivalirudin, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Renal dose adjustment required - predominantly cleared renally
- Increased stent thrombosis risk if infusion stopped abruptly
- No specific reversal agent available
- Use caution with concomitant antiplatelet agents
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | PCI Anticoagulation (Level A), Reduced Major Bleeding (Level A), and Acute Stent Thrombosis (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Bivalirudin Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/bivalirudin-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.